Japan’s Mochida Pharmaceutical announced that it has submitted a New Drug Application (NDA) to the China National Medical Products Administration (NMPA) for Epadel S (MND-21), a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation that is being jointly developed in China by Mochida and Sumitomo Pharma (Suzhou) Co, a Chinese subsidiary of Sumitomo Pharma Co.
As the clinical Phase III trial conducted in patients with severe hypertriglyceridemia in China has shown positive results, Mochida has submitted a New Drug Application for Epadel S.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze